EUCTR2005-004893-26-GB进行中（未招募）1 期
An open-label, non-comparative trial to evaluate the safety, efficacy and pharmacokinetics of FASLODEX (fulvestrant) in girls with progressive precocious puberty associated with McCune-Albright Syndrome.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Provision of written informed consent of parent/legal guardian and subject assent (as required by local law)
- •2.For patients consenting to participate in the genetic portion of the study, provision of an additional written informed consent specific for DNA sampling and genetic analysis.
- •3.Females less than or equal to 10 years of age (prior to 11th birthday) at the start of trial therapy (Visit 0).
- •4.Diagnosis of McCune-Albright Syndrome based on having the following clinical criteria:
- •·Precocious puberty evident before the age of 8 years
- •And at least one of the following clinical criteria:
- •·Café au lait spots
- •·Fibrous dysplasia
- •·Presence of Gsa mutation
- •5.Progressive precocious puberty associated with MAS. Progressive precocious puberty will be defined as:
- •oAn increase of at least one in the breast Tanner Stage over the observation period
- •oThe development or persistence of vaginal bleeding during the observation period.
- •6.At least one of the following two criteria must also be fulfilled:
- •oAdvanced bone age: defined as, bone age of at least 12 months beyond chronological age at the time of screening.
- •oRapid growth rate: a growth rate over the observation period that is more than 2 standard deviations above the mean for age, where the growth rate is defined as the change in height (or length) (in cm) divided by the change in time (annualized in years).
- •7.Patients are eligible provided they are in one of the following categories:
- •oReceived no previous treatment and have documented retrospective data of at least 6 months for bone age, Tanner Stage, height, weight, and vaginal bleeding (number of bleeding days).
- •oReceived no previous treatment and do not have documented retrospective data of at least 6 months for bone age, Tanner Stage, height, weight and vaginal bleeding (number of bleeding days) and can be observed for 6 months without treatment (i.e., 6-month observation period).
- •oDocumented progression on treatment with anastrozole, tamoxifen, testolactone, or other aromatase inhibitors, an anti-androgen, or a progestin requiring immediate treatment provided there exists retrospective data of at least 6 months for bone age, Tanner Stage, height, weight, and vaginal bleeding (number of bleeding days) and are off these agents for 1 month prior to first dose of study drug.
- •oPreviously treated with any drug for PPP in which therapy was stopped for at least 6 months with subsequent clinical evidence of progression of disease meeting entry criteria No. 5 and 6 and retrospective data of at least 6 months for bone age, Tanner Stage, height, weight, and vaginal bleeding (number of bleeding days).
- •8.If central precocious puberty (CPP) exists, the patient must have been on a GnRH analog (e.g., Lupron) for at least 6 months prior to study enrollment (date of written consent of parent/legal guardian and patient assent).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Male gender
- •2.Any prior treatment of PPP associated with MAS with fulvestrant
- •3.Concomitant treatment of PPP associated with MAS, with the exception of bisphosphonates for fibrous dysplasia and GnRH analogs in the case of CPP
- •4.Liver function tests (AST, ALT) at screening ³ 3´ the upper limit of the reference range for age
- •5.Platelet count at screening less than 100 ´ 109/L
- •6.International normalized ratio (INR) greater than 1.6.
- •7.History of bleeding diathesis or long-term anticoagulant therapy (other than antiplatelet therapy)
- •8.Any severe concomitant condition that makes it undesirable for the patient to participate in this study
- •9.Known hypersensitivity to any component of the study drug product
研究者
相似试验
进行中（未招募）
1 期
An open-label, non-comparative trial to evaluate the safety, efficacy and pharmacokinetics of FASLODEX (fulvestrant) in girls with progressive precocious puberty associated with McCune-Albright Syndrome.Progressive precocious puberty associated with McCune-Albright SyndromeEUCTR2005-004893-26-DEAstraZeneca AB30
进行中（未招募）
1 期
An open-label, non-comparative trial to evaluate the safety, efficacy and pharmacokinetics of FASLODEX (fulvestrant) in girls with progressive precocious puberty associated with McCune-Albright Syndrome.Ensayo abierto y no comparativo, para evaluar la seguridad, la eficacia y la farmacocinética de FASLODEX™ (fulvestrant) en niñas con pubertad precoz progresiva asociada al síndrome de McCune-AlbrightPubertad precoz progresiva asociada al síndrome de McCune-Albright.EUCTR2005-004893-26-ESAstraZeneca AB30
进行中（未招募）
1 期
An Open-label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of FASLODEX fulvestrant in Girls with Progressive Precocious Puberty Associated with McCune Albright Syndrome - D6992C00044Progressive Precocious Puberty Associated with McCune Albright SyndromeMedDRA version: 9.1Level: LLTClassification code 10044701Term: True precocious pubertyEUCTR2005-004893-26-ITASTRAZENECA30
进行中（未招募）
1 期
A clinical trial to evaluate the effect of OTL-200, a gene therapy treatment in patients with Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD)Metachromatic Leukodystrophy (MLD) is an autosomal recessive disorder caused by mutationsMedDRA version: 20.0Level: PTClassification code: 10067609Term: Metachromatic leukodystrophy Class: 100000004850CTIS2024-511971-13-00Orchard Therapeutics (Europe) Limited6
进行中（未招募）
1 期
A Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Mexiletine in Adolescents and Children with Myotonic DisordersMyotonic disorders: Nondystrophic myotonias (NDM) or myotonic dystrophies (DM, type 1 or type 2)ICD-10 code G71.1MedDRA version: 21.1Level: LLTClassification code 10028658Term: Myotonic disordersSystem Organ Class: 100000004852EUCTR2019-003757-28-FRupin Europe GmbH14